HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts

Jaira F. de Vasconcellos¹, Y. Terry Lee¹, Colleen Byrnes¹, Laxminath Tumburu²*, Antoinette Rabel¹, Jeffery L. Miller¹*

¹ Molecular Genomics and Therapeutics Section, Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, ² Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

* Current address: Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America

jm7f@nih.gov

Abstract

Induction of fetal hemoglobin (HbF) has therapeutic importance for patients with beta-hemoglobin disorders. Previous studies showed that let-7 microRNAs (miRNAs) are highly regulated in erythroid cells during the fetal-to-adult developmental transition, and that targeting let-7 mediated the up-regulation of HbF to greater than 30% of the total globin levels in human adult cultured erythroblasts. HMGA2 is a member of the high-mobility group A family of proteins and a validated target of the let-7 family of miRNAs. Here we investigate whether expression of HMGA2 directly regulates fetal hemoglobin in adult human erythroblasts. Let-7 resistant HMGA2 expression was studied after lentiviral transduction of CD34(+) cells. The transgene was regulated by the erythroid-specific gene promoter region of the human SPTA1 gene (HMGA2-OE). HMGA2-OE caused significant increases in gamma-globin mRNA expression and HbF to around 16% of the total hemoglobin levels compared to matched control transductions. Interestingly, no significant changes in KLF1, SOX6, GATA1, ZBTB7A and BCL11A mRNA levels were observed. Overall, our data suggest that expression of HMGA2, a downstream target of let-7 miRNAs, causes moderately increased gamma-globin gene and protein expression in adult human erythroblasts.

Introduction

Sickle cell disease (SCD) and the beta-thalassemias are among the most common genetic disorders worldwide [1, 2]. These diseases are caused by the occurrence of mutations in the adult globin gene [2–5]. Although many clinical trials are ongoing [6], the only drug currently approved by the Food and Drug Administration for the treatment of SCD is hydroxyurea, which is known to increase levels of fetal hemoglobin (HbF) [7]. HbF has a sparing effect in sickle hemoglobin polymerization [8], and HbF levels of >20% are sufficient to ameliorate the
pathogenesis of the disease [9]. In recent years, many advances have been made in the investigation of factors that regulate HbF levels. Genome-Wide Association Studies (GWAS) identified several relevant polymorphisms to the variation of human HbF levels, including the BCL11A locus [10, 11]. Additional studies included the correction of the SCD phenotype by the knockdown of BCL11A in adult mice [12], and the discovery of an erythroid-specific enhancer that regulates the genetic variation of BCL11A levels [13, 14]. More recent studies identified the transcription factor LRF/ZBTB7A as causing robust increases in the levels of HbF in human cultured erythroblasts [15]. Altogether, these studies provide new insights into candidate-therapeutic targets for the treatment of beta-hemoglobin disorders; however a clinically effective approach for the reactivation of HbF in adult erythroblasts is still missing.

In erythroid cells, the let-7 family of microRNAs (miRNAs) is highly regulated during the fetal-to-adult developmental transition, where let-7 family members are consistently up-regulated in adult blood compared to cord blood reticulocytes [16]. Additional studies demonstrated that the let-7 miRNAs, as well as LIN28A and LIN28B (proteins that bind and inhibit let-7 miRNAs) regulate HbF expression levels to >30% of the total hemoglobin produced in cultured erythroblasts from adult humans [17]. Furthermore, over-expression of LIN28A was also shown to ameliorate the hypoxia-related sickling of cultured mature erythrocytes from pediatric patients with sickle cell disease [18]. More recently, high LIN28B expression was associated with elevated levels of HbF in patients with juvenile myelomonocytic leukemia, thus identifying expression of LIN28B as the hallmark of a novel fetal-like molecular subgroup in this disease [19].

High Mobility Group AT-hook 2 (HMGA2) is a member of the HMGA non-histone chromatin protein family known as ‘architectural transcription factors’ and are downstream targets of the let-7 miRNAs. HMGA2 mRNA is negatively-regulated by the binding of let-7 miRNAs to the 3’-UTR region [20, 21]. Interestingly, HMGA2 mRNAs are subjected to alternative splicing modifications and form four different isoforms that vary concerning their 3’ structure, resulting in novel 3’-coding and -untranslated regions.

HMGA2 is known to both positively and negatively regulate the transcription of several genes by means of directly binding the DNA AT-hook domains (encoded by HMGA2 exons 1 to 3) to the minor groove of AT-rich regulatory elements, altering the DNA conformation or the chromatin structure [22–24]. During development, HMGA2 has been shown to have a role in the regulation of growth and adipogenesis in mammalian animal models [24, 25]. Furthermore, HMGA2 is involved in a wide variety of biological mechanisms, such as cell-cycle progression, cell proliferation, cell differentiation and senescence [22, 26]. Of note, over-expression of HMGA2 transcripts, possibly due to disruption of the let-7 miRNAs binding sites at the HMGA2 locus, accompanied an increased expression of endogenous HbF in a patient receiving lentiviral beta-globin gene therapy for the treatment of severe transfusion-dependent beta-thalassemia [27].

Here we investigated HMGA2 as a regulator of fetal hemoglobin. We observed moderate increases in gamma-globin gene expression and HbF levels in human adult cultured erythroblasts. Our data support that the LIN28-let-7 heterochronic pathway increases HbF, in part, by the targeting of erythroblast HMGA2 transcripts.

**Materials and Methods**

**Ethics Statement**

All related studies were performed after human subject review and Intramural National Institutes of Health Institutional Review Board approval. These studies were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all
research subjects prior to participation in this study. Peripheral blood CD34(+) cells from healthy adult human volunteers were mobilized and isolated using a Clinimax device as previously described [28]. All cell processing, isolation, and cryopreservation were performed by personnel in the Cell Processing Section of the National Institutes of Health Department of Transfusion Medicine.

**Cell culture**

Cryopreserved healthy adult human CD34(+) cells were cultured *ex vivo* in a serum-free system for 21 days consisting of three phases: phase I from days 0 to 7, phase II from days 7 to 14 and phase III from days 14 to 21, as previously described [17]. Cell counts were performed throughout the culture period in a Z1 Coulter Particle Counter (Beckman Coulter, Indianapolis, IN) following manufacturer’s instructions.

**Lentiviral erythroid promoter vector construction for HMGA2 over-expression**

Lentiviral constructs were designed for *let-7* resistant expression of HMGA2 variant 1 (HMGA2-OE) driven by the erythroid specific gene promoter region of the human *SPTA1* gene (GRCh38/hg38; chromosome 1: 158,686,528–158,687,488), with a matched empty vector control. HMGA2 variant 1 was chosen because it is the only HMGA2 variant with *let-7* binding sites in its 3’ UTR [20, 21]. Lentiviral backbone pLVX-IRES-Puro (Cat. 632183) was purchased from Clontech (Mountain View, CA). To generate the SPTA1-IRES-Puro plasmid (empty vector control), the CMV promoter from the pLVX-IRES-Puro vector was replaced with the human *SPTA1* promoter by directional cloning with ClaI and XhoI restriction enzymes as previously described [29]. The HMGA2 coding region with added Xhol and BamHI restriction sites for directional cloning was amplified by PCR from human genomic DNA with the following PCR primer pairs: HG2A 5’XhoI: 5’ ACCCTCGAGTATGAGCGCACG CGGTGAGGG 3’; V1HG2A 3’BamHI: 5’ CCGGATCCCTAGTCCTCTTC GGCAGACTCTTGTGA GGAT 3’ using CloneAmp HiFi PCR Premix (Clontech). The HMGA2 PCR product was digested with Xhol and BamHI restriction enzymes (New England Biolabs, Ipswich, MA) following manufacturer’s protocol and cleaned up with MinElute Reaction Cleanup Kit (Qiagen, Valencia, CA), followed by cloning into the pLVX-SPTA1-IRES-Puro vector to generate a pLVX-SPTA1-HMGA2-IRES-Puro plasmid.

**HMGA2 virus production and lentiviral transduction**

Virus production was performed as previously described [29]. Briefly, the plasmid mixture was prepared for co-transfection in HEK293T cells (Thermo Scientific, Waltham, MA) following the manufacturer’s instructions for the Calcium Phosphate Transfection Kit (Life Technologies, Grand Island, NY). The co-transfection mixture consisted of the vector plasmid (empty vector control or HMGA2-OE vector) with CAG kGP1.1R, CAG4 RT2 and CAGGS vsv-g packaging helper virus plasmids [30, 31]. The lentivirus-containing supernatant was concentrated following the Lenti-X Concentrator (Clontech) manufacturer’s protocol and resuspended in 1/100 of the original supernatant volume in phase I culture medium. The presence of lentiviral particles was confirmed using the Lenti-X GoStix (Clontech) following the manufacturer’s instructions. Cryopreserved CD34(+) cells were thawed and seeded at a density of 250,000 cells/ml in phase I culture medium. On culture day 3, cells were resuspended at a density of 2,000 cells/μl in phase I culture medium and transduced with lentiviral particles (an estimated MOI of 5 was calculated for the viral transductions). On the day after transduction, cells were resuspended in 4.0 ml phase I culture medium containing puromycin and transferred on
day 7 into phase II culture medium without puromycin. For each condition, a puromycin selected control of mock-transduced cells was cultured in matched conditions until the end of phase II and analyzed to confirm puromycin selection by flow cytometry.

Flow cytometry analyses
Erythroid differentiation was assessed with transferrin receptor (CD71) and glycophorin A (GPA) antibodies (Invitrogen, Carlsbad, CA) on culture days 14 and 21 using the BD FACSAria I flow cytometer (BD Biosciences, San Jose, CA) as previously described [32]. Enucleation was quantitated by thiazole orange staining (Sigma) on culture day 21. To assess fetal hemoglobin, cells were stained with antibody directed against HbF (Invitrogen).

Quantitative PCRs
Total RNA was isolated using miRNeasy mini kit with QIAzol following manufacturer’s instructions (Qiagen) and quantitated by reading absorbance at 260 nm in the spectrophotometer. In all samples, complementary DNA (cDNA) was synthesized using SuperScript III reverse transcriptase (Thermo Fisher) from the same amount of total RNA following manufacturer’s instructions and as previously described [28]. Quantitative real-time PCR amplification was carried out in a 7700 Sequence Detection System using TaqMan Universal PCR Master Mix (Thermo Fisher) used following manufacturer’s instructions. Q-RT-PCR assays and conditions were performed as previously described [17, 33, 34], with the addition of ZBTB7A (Hs00792219_m1) Assay-on-Demand Gene Expression Product (Thermo Fisher/Applied Biosystems, Grand Island, NY) for gene expression analyses. For the let-7 family of miRNAs, cDNA synthesis and Q-RT-PCR assays and conditions were performed as previously described [16] for let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i and miR-98. In all Q-RT-PCR reactions, absolute quantification for each transcript was determined by comparison with a standard curve that was run in parallel with biological samples as previously described [28]. For each let-7 family member, standard curves were constructed on the basis of the synthetic targeted mature miRNA oligonucleotide of known concentration (1:10 serial dilutions, n = 6). Reactions were performed in triplicate. A file containing each of the standard curves statistics is included as S1 Appendix.

Western blot analysis
Nuclear and cytoplasmic extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce Biotechnology, Rockford, IL) from culture day 14 erythroblasts as previously described [17]. Equal amounts of protein were separated following the Western blot protocol as previously described [17]. Blots were probed with antibody against HMGA2 (Abcam, Cambridge, MA). Lamin B1 was used as loading control (Abcam, Cambridge, MA).

Confocal analysis
For confocal microscopy, slides containing 70,000 sorted live cells on culture day 14 were fixed with 3.7% paraformaldehyde in PBS (Electron Microscopy Sciences, Hatfield, PA) and permeabilized with 2% BSA/PBS containing 0.1% Triton X (Thermo Fisher Scientific, Grand Island, NY). After cell permeabilization, slides were probed with antibody against human HMGA2 (1:500, ab184616, Abcam) overnight at 4°C in 2% BSA/PBS solution. Slides were incubated with secondary antibody against rabbit IgG (H+L) conjugated with CF-555 (1:500, Sigma) in 2% BSA/PBS solution for one hour at room temperature. After secondary antibody incubation, slides were washed three times in PBS and once in distilled water then mounted
with ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific). Laser scanned confocal images were obtained from LSM 5 Live Duoscan (Carl Zeiss, Oberkochen, Germany) and analyzed with Zen2007 software.

**HPLC for adult and fetal hemoglobins**
HPLC samples were prepared and analyzed as previously described [28, 35].

**Statistical analysis**
Replicates are expressed as mean ± SD values and significance was calculated by one- or two-tailed paired Student’s t-test.

**Results**

**HMGA2 over-expression has minor effects in erythroblast in vitro differentiation and enucleation**

HbF regulation in humans remains an active area of investigation. Recently, the heterochronic LIN28-let-7 pathway that has been associated with developmental timing events in *C. elegans* has been reported to be involved in the modulation of HbF levels [17, 19]. Since the LIN28 RNA-binding proteins negatively regulate the let-7 family of miRNAs [36] and the let-7 miRNAs are negative regulators of HMGA2 [21], we investigated the role of HMGA2 in the regulation of HbF. For this purpose, erythroid-specific over-expression of HMGA2 was performed and compared to empty vector controls. To prevent degradation in the adult CD34(+) cells, the 3′-untranslated region (UTR) of the gene where the let-7 miRNAs binding sites are located was excluded, and only the open reading frame from the HMGA2 variant 1 was used in the over-expression lentivirus transgene, keeping intact the region encoding the DNA-binding AT-hook domains. Transductions were performed in CD34(+) cells from adult healthy volunteers cultivated *ex vivo* in erythropoietin-supplemented serum-free media for 21 days. Expression of transgenic HMGA2 (HMGA2-OE) was confirmed by Q-RT-PCR (empty vector control: below detection limits; HMGA2-OE: 2.51E+04 ± 3.44E+04 copies/ng) and Western analyses at culture day 14 (Fig 1). Pancellular HMGA2 expression was demonstrated by confocal analysis of HMGA2-OE compared to control transduction (S1 Fig).

Cell proliferation and erythroblast differentiation were compared between empty vector control samples and HMGA2-OE. Cell counts at culture day 14 showed no significant differences between HMGA2-OE and empty vector control transductions (S2 Fig). Furthermore, erythroblast maturation characterized by expression and gradual loss of transferrin receptor (CD71) and expression of glycophorin A (GPA) on the cell surface was analyzed in the empty vector control and HMGA2-OE samples at day 14 and at the end of the culture period (Fig 2A), as well as enucleation was assessed by thiazole orange (TO) staining in the empty vector control and HMGA2-OE samples at the end of the culture period (Fig 2B). Maturation was equivalent among HMGA2-OE and empty vector control cells at culture day 14. However, less terminal maturation and enucleation were detected by culture day 21 [Average % CD71(+) and GPA(+): empty vector control: 54.4 ± 9.7, HMGA2-OE: 71.6 ± 11.1, p = 0.01; Average % CD71(-) and GPA(+): empty vector control: 45.6 ± 9.7, HMGA2-OE: 28.3 ± 11.1, p = 0.01]. Despite the decreased maturation, HMGA2-OE cells maintained the ability to enucleate to an average of 35.2 ± 17.0% in the *ex vivo* culture conditions.
HMGA2 over-expression moderately regulates HbF levels in human adult erythroblasts

To investigate the effects of HMGA2-OE in the expression levels of the globin mRNAs in cultured adult erythroblasts, Q-RT-PCR analysis of the alpha- and beta-globin genes was performed at culture day 14. No major differences were observed in mu-, theta-, zeta-, delta- and epsilon-globin transcripts in HMGA2-OE samples compared to empty vector control transductions (Fig 3A and 3B). Average increases of 23% and 27% in mRNA levels of alpha- and beta-globin were detected, respectively, but those increases did not reach statistical significance due to donor variability (S3A and S3B Fig). In contrast, gamma-globin mRNA was consistently
increased in each donor resulting in an average increase of 189% observed in HMGA2-OE compared to controls (empty vector control: 5.02E+05 ± 8.62E+04 copies/ng; HMGA2-OE: 1.45E+06 ± 7.31E+05 copies/ng; p = 0.037; Fig 3B and S3C Fig). HPLC analyses at culture day 21 demonstrated a modest but significant increase in HbF levels in HMGA2-OE compared to controls (empty vector control: 5.41 ± 2.15%; HMGA2-OE: 16.53 ± 4.43%; p = 0.003; Fig 3C–3E and S3D Fig), which is consistent with the increase in gamma-globin mRNA levels. In addition, HbF staining by flow cytometry at culture day 21 demonstrated that HMGA2-OE has a pancellular expression of HbF compared to the control transductions (Fig 3F). Overall, the data showed here supports the notion that the LIN28-let-7 pathway regulates HbF, at least in part, by targeting of the erythroblast HMGA2 transcripts.

HMGA2 over-expression has minor effects in erythroid- and HbF-related transcription factors

To determine if HMGA2-OE acts via known regulators of gamma-globin, Q-RT-PCR analyses were performed for expression of the LIN28 genes, the let-7 family of miRNAs as well as several erythroid-related transcription factors. LIN28A and LIN28B were not affected by HMGA2-OE

Fig 2. Erythroid-expression of HMGA2 leads to slightly lower levels of terminal maturation and enucleation compared to control transductions during in vitro erythroblast differentiation. Representative donor flow cytometry analyses of (A) empty vector control and HMGA2-OE at culture days 14 and 21 stained with anti-transferrin receptor (CD71) and anti-glycophorin A (GPA) antibodies. (B) Enucleation of empty vector control and HMGA2-OE transductions assessed by staining of culture day 21 cells with thiazole orange. Percentages shown in the figure correspond to one representative donor, average values are shown in the text. C = empty vector control transduction; HMGA2-OE = HMGA2 over-expression.

doi:10.1371/journal.pone.0166928.g002
Fig 3. Enforced expression of HMGA2 regulates gamma-globin mRNA and pancellular HbF levels in adult human erythroblasts cultivated ex vivo. Quantitation of copy number per nanogram cDNA (copies/ng cDNA) by Q-RT-PCR analyses was performed at culture day 14 for (A) alpha-, mu-, theta- and zeta-globins, and (B) beta-, delta-, gamma- and epsilon-globins in HMGA2-OE and empty vector control transductions. Representative HPLC profile of hemoglobin collected at culture day 21 from (C) empty vector control transductions and (D) HMGA2-OE. (E) Average percentage of HbF levels detected by HPLC analysis. (F) Representative flow cytometry dot plots of empty vector control transductions (left panel) and HMGA2-OE (right panel) at culture day 21 stained for fetal hemoglobin. Open bar represents empty vector control and black bar represents HMGA2-OE. Mean value ± SD of four independent donors for each condition. P-value was calculated using one-tailed paired Student’s t-test. C = empty vector control transduction; OE = HMGA2 over-expression. *p<0.05.

doi:10.1371/journal.pone.0166928.g003
remaining below the detection limits. Likewise, no significant changes were detected in the levels of the let-7 family of miRNAs in HMGA2-OE compared to empty vector control samples (Fig 4). These results demonstrate that upon high-level erythroblast expression of HMGA2 there is no feedback loop that regulates LIN28 transcripts or the let-7 miRNAs. In addition, the expression pattern of the transcription factors KLF1, SOX6, GATA1, ZBTB7A and BCL11A were investigated and, despite a down-regulation trend in the expression level of these transcription factors, there were no statistically significant changes detected in HMGA2-OE compared to empty vector control transductions (Fig 5A–5E). Overall, HMGA2-OE caused mild changes in several transcription factors that are known regulators of HbF, but none of the changes reached statistical significance in this study.

**Discussion**

Understanding the molecular processes controlling the fetal-to-adult hemoglobin transition is crucial to determine the drivers and effectors of HbF, which have the potential to be used in the treatment of beta-hemoglobin disorders. Here we focus on recent discoveries that highlight the interplay between the heterochronic LIN28-let-7 pathway and the regulation of HbF. Our results demonstrate that HMGA2, a downstream target of the let-7 miRNAs [37], plays a moderate role in the modulation of gamma-globin and HbF levels. Importantly, HMGA2 had only modest effects in the activation of HbF, so these results are unable to fully explain the more robust HbF effects of let-7 miRNA suppression by LIN28 in the same culture model [17].

HMGA2 is physiologically expressed during embryonic and fetal developmental stages, and it is down-regulated to very low or absent levels in normal adult tissues [38]. In addition, Hmga2 transcripts are differentially expressed between fetal and adult mice hematopoietic stem cells [39]. Here we expressed a let-7-resistant HMGA2 variant 1 driven by the erythroid specific gene promoter region of the human SPTA1 gene. Of note, HMGA2 proteins do not have a direct transcriptional activation function; however, they can control gene expression by interaction with DNA and transcription factors (TFs) to form complexes that support the TFs...
with binding to the DNA [40], or exclusively interacting with the TFs and, consequently, increasing their affinity to bind to its target DNA [41].

It has been shown that transgenic mice carrying a 3’UTR-truncated Hmga2 cDNA showed proliferative hematopoiesis, erythropoietin-independent erythroid colony formation, as well as hypercellular bone marrow and splenomegaly [42]. Conversely, similar hyperproliferative
changes were not associated with increased expression of a truncated HMGA2 protein, accompanied by an increase in expression of endogenous HbF, in a patient receiving lentiviral beta-globin gene therapy for the treatment of beta-thalassemia [27]. We report here that erythroid-specific-let-7-resistant HMGA2 over-expression had only minor effects in ex vivo erythropoiesis and enucleation. While mRNA levels of alpha- and beta-globin genes were both increased upon HMGA2 over-expression, these increases were most likely the result of donor variability (S3 Fig). However, a moderate and consistent activation of gamma-globin expression was observed upon HMGA2 over-expression in all donors, as well as increased and pancellular HbF levels to an average of 16% of the total hemoglobin produced. Despite the high HMGA2 protein levels detected in each donor’s cells, HbF was increased to levels lower than those observed in previous studies directly targeting LIN28 or let-7 miRNAs performed under similar culture conditions [17]. Due to a modest effect on HbF with HMGA2-OE, additional factors are being sought that may act in combination with HMGA2 for the activation of HbF in adult erythroblasts, such as other downstream mRNA targets of the let-7 family of miRNAs.

Over-expression of HMGA2 did not significantly affect the levels of LIN28 or any of the let-7 family members, suggesting that the effects were not mediated by feedback regulation within the let-7 regulatory circuit. To explore potential downstream effects of HMGA2 over-expression in adult erythroblasts, the expression levels of transcription factor regulators of HbF were investigated. KLF1, SOX6, GATA1, ZBTB7A and BCL11A mRNA levels were not significantly reduced with the over-expression of HMGA2. We interpreted these results as an indication that HMGA2 effects are not primarily mediated by a singular transcription factor in this group. Alternatively, the subtle differences in the erythroblast differentiation (Fig 2) mediated by HMGA2-OE may influence the effects of transcription factors upon globin gene regulation as well as HbF levels.

Finally, our studies on HMGA2 add to recent efforts aimed toward developing an experimental bridge that connects the ancient and well-conserved LIN28-let-7 developmental timing circuit with the abundant knowledge of globin gene regulation during human ontogeny. Importantly, since direct targeting of the let-7 miRNAs in adult erythroblasts causes more robust effects in the reactivation of HbF levels, the results shown here suggest that HMGA2 expression is not sufficient to fully explain the downstream effects of the LIN28-let-7 circuit in the regulation of HbF levels.

Supporting Information

S1 Appendix. Quantitative PCRs standard curves statistics.
(XLSX)

S1 Fig. HMGA2 over-expression has a pancellular distribution in adult human erythroblasts cultivated ex vivo. Confocal analysis of empty vector control transduction (control) and HMGA2 over-expression (HMGA2-OE) were performed at culture day 14. Confocal images of control transduction and HMGA2 over-expression cells were stained with DAPI (4’,6-diamidino-2-phenylindole) (blue) and HMGA2 (green).
(TIF)

S2 Fig. Erythroid-expression of HMGA2 demonstrates comparable levels of cell proliferation compared to control transductions. Cell proliferation was assessed by cell counts (cells/mL) performed at culture day 14. Open bar represents empty vector control and black bar represents HMGA2-OE. Mean value ± SD of four independent donors for each condition. C = empty vector control transduction; OE = HMGA2 over-expression.
(TIF)
S3 Fig. Effects of HMGA2 over-expression on the levels of (A) alpha-, (B) beta-, and (C) gamma-globin transcripts according to individual donors. Quantitation of copy number per nanogram cDNA (copies/ng cDNA) was performed by Q-RT-PCR at culture day 14. Standard deviation was calculated for each sample in triplicate reactions. (D) Effects of HMGA2 over-expression on the levels of fetal hemoglobin (values for each donor are shown). Fetal hemoglobin levels were measured by HPLC analysis of hemoglobin collected at culture day 21 from HMGA2-OE and empty vector control transductions. Open bars represent empty vector control and black bars represent the HMGA2 over-expression. C = empty vector control transduction; OE = HMGA2 over-expression.

Author Contributions

Conceptualization: JLM.
Formal analysis: JFV YTL CB.
Funding acquisition: JLM.
Investigation: JFV YTL CB.
Methodology: JFV YTL CB LT AR.
Project administration: JLM.
Supervision: JLM.
Writing – original draft: JFV JLM.
Writing – review & editing: JFV YTL CB JLM.

References

1. Pleasant s S. Epidemiology : a moving target. Nature. 2014; 515(7526):S2–3. Epub 2014/11/13. doi: 10. 1038/515S2a PMID: 25390139.
2. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999; 341(2):99–109. Epub 1999/07/08. doi: 10. 1056/nejm199907083410207 PMID: 10395635.
3. Pauling L, Itano HA, et al. Sickle cell anemia a molecular disease. Science. 1949; 110(2865):543–8. Epub 1949/11/25. PMID: 1539538.
4. Neel JV. The Inheritance of Sickle Cell Anemia . Science. 1949; 110(2846) :64–6. Epub 1949/07/15. doi: 10. 1126/science.110.2846.64 PMID: 17774955.
5. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956; 178(4537):792–4. Epub 1956/10/13. PMID: 13369537.
6. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016; 127(7):810–9. Epub 2016/01/14. doi: 10.1182/blood-2015-09-618553 PMID: 26758919.
7. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996; 75(6):260–9. Epub 1996/11/01. PMID: 8982148.
8. Sewchand LS, Johnson CS, Meiselman HJ. The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes. Blood Cells. 1983; 9(1):147–66. Epub 1983/01/01. PMID: 6190521.
9. Noguchi CT, Rodgers GP, Serjeant G, Scheckter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988; 318(2):96–8. Epub 1988/01/14. doi: 10.1056/ nejm198801143180207 PMID: 2447498.
10. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-
thalassemia. Proc Natl Acad Sci U S A. 105. United States2008. p. 1620–5. doi: 10.1073/pnas.0711566105 PMID: 18245381

11. Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 39. United States2007. p. 1197–9.

12. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 334. United States2011. p. 993–6. doi: 10.1126/science.1211053 PMID: 21998251

13. Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013; 342(6155):253–7. Epub 2013/10/12. doi: 10.1126/science.1242088 PMID: 24115442; PubMed Central PMCID: PMCPMC4018826.

14. Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015; 527(7577):192–7. Epub 2015/09/12. doi: 10.1038/nature15521 PMID: 26375006; PubMed Central PMCID: PMCPMC4644101.

15. Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. 2016; 351(6270):285–9. Epub 2016/01/28. doi: 10.1126/science.aad3312 PMID: 26816381.

16. Noh SJ, Miller SH, Lee YT, Goh SH, Marincola FM, Stroncek DF, et al. Let-7 microRNAs are developmentally regulated in circulating human erythroid cells. J Transl Med. 7. England2009. p. 98. doi: 10.1186/1479-5876-7-98 PMID: 19939273

17. Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood. 2013; 122(6):1034–41. Epub 2013/06/27. doi: 10.1182/blood-2012-12-472308 PMID: 23798771; PubMed Central PMCID: PMCPMC379030.

18. de Vasconcellos JF, Fasano RM, Lee YT, Kaushal M, Byrnes C, Meier ER, et al. LIN28A Expression Reduces Sickling of Cultured Human Erythrocytes. PLoS One. 2014; 9(9):e106924. Epub 2014/09/05. doi: 10.1371/journal.pone.0106924 PMID: 25188417; PubMed Central PMCID: PMCPMC4154803.

19. Helsmoortel HH, Bresolin S, Lammens T, Cave H, Noellke P, Caye A, et al. LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood. 2015. Epub 2015/12/30. doi: 10.1182/blood-2015-09-667808 PMID: 26712910.

20. Mayr C, Heman MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315(5818):1576–9. Epub 2007/02/27. doi: 10.1126/science.1137999 PMID: 17320203; PubMed Central PMCID: PMCPMC2556962.

21. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007; 21(9):1025–30. Epub 2007/04/18. doi: 10.1101/gad.1540407 PMID: 17437991; PubMed Central PMCID: PMCPMC1855228.

22. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007; 7(12):899–910. Epub 2007/11/16. doi: 10.1038/nrc2271 PMID: 18004397.

23. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, et al. Nuclear phosphoproteins HMGA2 and HMGI-C and their relationship with chromatin structure and cancer. FEBS Lett. 2004; 574(1–3):1–8. Epub 2004/09/10. doi: 10.1016/j.febslet.2004.08.013 PMID: 15358530.

24. Zhou X, Benson KF, Przybysz K, Liao J, Hou Y, Cherath L, et al. Nuclear structure and expression of the murine Hmgi-c gene. Nucleic Acids Res. 1996; 24(20):4071–7. Epub 1996/10/15. PMID: 8918814; PubMed Central PMCID: PMCPMC146186.

25. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature. 1995; 376(6543):771–4. Epub 1995/08/31. doi: 10.1038/376771a0 PMID: 7651355.

26. Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006; 126(3):503–14. Epub 2006/08/12. doi: 10.1016/j.cell.2006.05.052 PMID: 16901784.

27. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 467. England2010. p. 318–22. doi: 10.1038/nature09326 PMID: 20844535.

28. Wojda U, Noel P, Miller JL. Fetal and adult hemoglobin production during adult erythropoiesis: coordinate expression correlates with cell proliferation. Blood. 2002; 99(8):3005–13. Epub 2002/04/04. PMID: 11929793.

29. Lee YT, de Vasconcellos JF, Byrnes C, Kaushal M, Rabel A, Tumburu L, et al. Erythroid-Specific Expression of LIN28A Is Sufficient for Robust Gamma-Globin Gene and Protein Expression in Adult
HMGA2 Increases Fetal Hemoglobin Levels

Erythroblasts. PLoS One. 2015; 10(12):e0144977. Epub 2015/12/18. doi: 10.1371/journal.pone.0144977 PMID: 26675483.

30. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193–9. Epub 1991/12/15. PMID: 1660837.

31. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther. 5. United States2002. p. 242–51. doi: 10.1006/mthe.2002.0549 PMID: 11863413

32. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 114. United States2009. p. 181–6. doi: 10.1182/blood-2008-12-195503 PMID: 19414861

33. Sripichai O, Kiefer CM, Bhanu NV, Tanno T, Noh SJ, Goh SH, et al. Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. Blood. 114. United States2009. p. 2299–306. doi: 10.1182/blood-2009-05-219386 PMID: 19597182

34. Goh SH, Lee YT, Bhanu NV, Cam MC, Desper R, Martin BM, et al. A newly discovered human alpha-globin gene. Blood. 2005; 106(4):1466–72. Epub 2005/04/28. doi: 10.1182/blood-2005-03-0948 PMID: 15855277; PubMed Central PMCID: PMCPmc1895206.

35. Lee YT, Kim KS, Byrnes C, de Vasconcellos JF, Noh SJ, Rabel A, et al. A synthetic model of human beta-thalassemia erythropoiesis using CD34+ cells from healthy adult donors. PLoS One. 2013; 8(7): e68307. Epub 2013/07/19. doi: 10.1371/journal.pone.0068307 PMID: 23861885; PubMed Central PMCID: PMCPmc3704632.

36. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011; 147(5):1066–79. Epub 2011/11/29. doi: 10.1016/j.cell.2011.10.039 PMID: 22118463; PubMed Central PMCID: PMCPmc3227872.

37. Boyerinas B, Park SM, Shomron N, Hedegaard MM, Vinther J, Andersen JS, et al. Identification of let-7-regulated oncifetal genes. Cancer Res. 2008; 68(8):2587–91. Epub 2008/04/17. doi: 10.1158/0008-5472.can-08-0264 PMID: 18413726.

38. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996; 149(3):779–86. Epub 1996/09/01. PMID: 8780382; PubMed Central PMCID: PMCPMC1865134.

39. Copley MR, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol. 2013; 15 (8):916–25. Epub 2013/07/03. doi: 10.1038/ncb2783 PMID: 23811688.

40. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell. 1992; 71(5):777–89. Epub 1992/11/27. PMID: 1330326.

41. Chin MT, Pelliacani A, Wang H, Lin SS, Jain MK, Perrella MA, et al. Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J Biol Chem. 1998; 273(16):9755–60. Epub 1998/05/23. PMID: 9545312.

42. Ikeda K, Mason PJ, Bessler M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011; 117(22):5860–9. Epub 2011/04/05. doi: 10.1182/blood-2011-02-334426 PMID: 21460244; PubMed Central PMCID: PMCPMC3112035.